Skip to Main content Skip to Navigation
Journal articles

Synergistic inactivation of AXL: a (cross)road to cure ovarian cancer?

Chiara Zurzolo 1, * 
* Corresponding author
Abstract : Comment on: The tumour suppressor OPCML promotes AXL inactivation by the phosphatase PTPRG in ovarian cancer. [EMBO Rep. 2018] Inhibition of the receptor tyrosine kinase AXL, a key molecular driver of ovarian cancer, has recently been highlighted as promising therapeutic strategy. In this issue of EMBO Reports, Antony et al 1 have identified a novel mechanism of inhibition of AXL, wherein the GPI‐anchored tumour suppressor OPCML sequesters AXL into specialised plasma membrane domains where the phosphatase PTPRG is located, therefore facilitating AXL dephosphorylation. This [...]
Document type :
Journal articles
Complete list of metadata
Contributor : Reine BOUYSSIE Connect in order to contact the contributor
Submitted on : Monday, August 5, 2019 - 1:09:08 PM
Last modification on : Thursday, April 7, 2022 - 10:10:37 AM

Links full text




Chiara Zurzolo. Synergistic inactivation of AXL: a (cross)road to cure ovarian cancer?. EMBO Reports, EMBO Press, 2018, 19 (8), pp.e46492. ⟨10.15252/embr.201846492⟩. ⟨pasteur-02263624⟩



Record views